Login to Your Account

Dystrophin no more?

The saga that unfolded during last week's Peripheral and Central Nervous System Drugs Advisory Committee not only left Biomarin Pharmaceutical Inc. twisting in the wind as the company awaits the FDA's decision on Kyndrisa, but also raised a bigger question for companies pursuing therapies to treat DMD.

more »


Partners in Focus